Entrectinib’s domestic marketing status and related information

Entrectinib is a targeted therapy drug that is mainly used to treat certain cancers, such as non-small cell lung cancer (NSCLC) and other cancers carrying ROS1 or NTRK gene mutations. The drug has been approved by the National Medical Products Administration of China (NMPA) and will be officially launched in China in the near future. This approval provides new treatment options for patients with the above-mentioned gene mutations and has a positive impact on the domestic cancer treatment field.

in the country, the launch of entrectinib marks the further popularization of targeted drug therapy. Patients can purchase the drug at hospital pharmacies, and entrectinib has been included in medical insurance, reducing the patient's financial burden. Despite this, the market price of the drug is still relatively expensive, about 20,000 yuan per box. The specific price and medical insurance reimbursement ratio may vary according to policy differences in the patient's region, so it is recommended that patients consult the local hospital pharmacy to obtain accurate cost information before purchasing.

In foreign markets, there are some relatively cheap generic versions of entrectinib, especially the Lao version. The price of the Lao version of entrectinib is much lower than that of the original drug. The price of the drug with the specification of 100mg*60 tablets is about more than 1,000 yuan, which is a more economical choice for patients. Although generic drugs are cheaper, their drug ingredients and efficacy are basically the same as the original drugs, so the Lao version of entrectinib is a viable alternative for patients who require long-term treatment.

In general, entrectinib has been officially launched in China, and certain financial support has been provided to patients through medical insurance policies. Although brand-name drugs are more expensive, overseas generic drugs provide affordable alternatives. Patients can choose the appropriate version according to their own conditions when purchasing, and communicate closely with the doctor during the treatment process to ensure the best treatment plan is selected.

Reference materials:https://www.roche.com/products/rozlytrek